Effect of nicotinamide riboside supplementation in dilated cardiomyopathy patients to CERP, Chromadex Inc. USA

Not Applicable

Conditions: Health Condition 1: I43- Cardiomyopathy in diseases classified elsewhere

Registration Number: CTRI/2023/04/051385

Lead Sponsor: Chromadex Inc. USA

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Meeting criteria for dilated cardiomyopathy (DCM) :

a.Left ventricular ejection fraction <45%

b.Left ventricular enlargement (A left ventricular end-diastolic dimension > 112% predicted value corrected for age and body surface area).

c.Having conventional risk factors for DCM, including obesity, routinely treated hypertension, alcohol use, pregnancy or the peripartum period, or left ventricular noncompaction.

2.Any age (including children)

3.Ability to give informed consent

Exclusion Criteria

1.Coronary artery disease (CAD) causing ischemic cardiomyopathy ( > 50% narrowing, any major epicardial coronary artery)

2.Primary valvular disease

3.Adriamycin or other cardiotoxic drug exposure

4.Other forms of cardiomyopathy: Hypertrophic, Restrictive, or Arrhythmogenic Right

5.Ventricular Dysplasia/Cardiomyopathy

6.Congenital heart disease

7.Other detectable causes of dilated cardiomyopathy, including sarcoid and hemochromatosis.

8.Other active multi-system disease that may cause DCM (e.g., active connective tissue disease).

9.Severe and untreated or untreatable hypertension

10.Absence of systemic hypertension( >160/100 mm Hg)

11.Pericardial diseases

12.Cor pulmonale

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study will serve as the first human clinical trial done in DCM patients using NR supplementation. Also this study will be one of a kind in evaluating the correlation of blood sirtuin and/or NAD+ concentration with DCM associated CHF progression.Timepoint: Day 0, 28, 56 and 84

Secondary Outcome Measures